$OMER earnings report

YARTEMLEA net product sales reached $35,934 thousand in Q3 2026 and operating income turned positive at $4,501 thousand, while a $62.0 million non-cash derivative loss drove a GAAP net loss of $(57,356) thousand. AlphAI read Omeros's Q3 FY2026 filing as mixed. 2 quarters are on record below.

Q3 FY2026

AlphAI · Earnings readOMER · Q3 2026 · ended 2026-09-30

YARTEMLEA net product sales reached $35,934 thousand in Q3 2026 and operating income turned positive at $4,501 thousand, while a $62.0 million non-cash derivative loss drove a GAAP net loss of $(57,356) thousand.

→Mixed quarter

Product revenue grew sequentially for a second period and operating income was positive, with operating cash flow of $13.3 million. The GAAP net loss of $(57,356) thousand, driven by a $62.0 million non-cash loss on the fair value of financial instruments, and a higher gross-to-net adjustment of 14.0% keep the quarter mixed. The company also disclosed a negative CHMP opinion in October 2026.

Revenue
$41.8M
29.6% q/q
YARTEMLEA (net product sales, the only product revenue line reported)
$35,934 thousand (Q3 2026); $74,356 thousand (nine months 2026)
26% q/q
EPS · non-GAAP
$0.06

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Gross YARTEMLEA revenue, Q3 2026other$41.8M29.6%–
Product sales, net, Q3 2026GAAP$35.93M26%–
Product sales, net, nine months 2026GAAP$74.36M––
Gross-to-net adjustment, Q3 2026other14.0%––
Cost of product sales, Q3 2026GAAP$826K––
Cost of product sales, nine months 2026GAAP$2.21M––
Research and development, Q3 2026GAAP$16.06M––
Research and development, nine months 2026GAAP$43.22M––
Selling, general and administrative, Q3 2026GAAP$14.55M––
Selling, general and administrative, nine months 2026GAAP$41.77M––
R&D and SG&A combined, Q3 2026 (as printed in MD&A)GAAPapproximately $30.6 million––
Total costs and expenses, Q3 2026GAAP$31.43M––
Total costs and expenses, nine months 2026GAAP$87.20M––
Income (loss) from operations, Q3 2026GAAP$4.50M––
Income (loss) from operations, nine months 2026GAAP−$12.85M––
Interest and other income, Q3 2026GAAP$1.87M––
Interest and other income, nine months 2026GAAP$7.97M––
Interest expense, net of remeasurement adjustments and other, Q3 2026GAAP−$6.22M––
Interest expense, net of remeasurement adjustments and other, nine months 2026GAAP−$19.70M––
Net gain (loss) on change in fair value of financial instruments, Q3 2026GAAP−$62.02M––
Net gain (loss) on change in fair value of financial instruments, nine months 2026GAAP$22.57M––
Loss on early extinguishment of 2029 Notes, Q3 2026GAAP−$1.91M––
Loss on early extinguishment of 2029 Notes, nine months 2026GAAP−$3.80M––
Net loss from continuing operations, Q3 2026GAAP−$63.83M––
Net loss from continuing operations, nine months 2026GAAP−$5.94M––
Net income (loss) from discontinued operations, Q3 2026GAAP$6.47M––
Net income (loss) from discontinued operations, nine months 2026GAAP$17.88M––
GAAP net income (loss), Q3 2026GAAP−$57.36M––
GAAP net income (loss), nine months 2026GAAP$11.94M––
GAAP net income (loss) per share, basic, Q3 2026GAAP$(0.79)––
GAAP net income (loss) per share, diluted, nine months 2026GAAP$0.13––
Non-GAAP adjusted net income (loss), Q3 2026non-GAAP$4.66M––
Non-GAAP adjusted net income (loss), nine months 2026non-GAAP−$10.64M––
Non-GAAP adjusted net income (loss) per share, basic, Q3 2026non-GAAP$0.06––
Non-GAAP adjusted net income (loss) per share, basic, nine months 2026non-GAAP$(0.15)––
Operating cash flow, Q3 2026 (not labelled GAAP in filing)other$13.3M––
Cash and short-term investments at September 30, 2026other$95.3M––

Segments

SegmentRevenueq/qy/y
YARTEMLEA (net product sales, the only product revenue line reported)Net revenue increased 26% to $35.9 million from $28.5 million in the second quarter. The company states that the gross-to-net adjustment rose to 14.0% from 11.5% because of higher purchases by 340B Drug Pricing Program entities, consistent with its goals of increasing outpatient utilization and expanding its customer base.$35,934 thousand (Q3 2026); $74,356 thousand (nine months 2026)26%–

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

Capital returns

  • In June and July 2026 the company entered into privately negotiated agreements to repurchase $30.5 million aggregate principal amount of 2029 Notes for a total purchase price of $60.2 million, plus accrued and unpaid interest of $0.2 million. Both transactions closed in July 2026.
  • Approximately $40.3 million aggregate principal amount of 2029 Notes remains outstanding after the repurchases.
  • The company states that the repurchases eliminated approximately $8.6 million in future interest payment obligations and reduced the shares issuable on conversion of the 2029 Notes by 4.9 million shares, from 11.4 million to 6.5 million.
  • During the first half of 2026 the company repurchased more than 843,000 shares of common stock at a volume-weighted average price of $11.70 per share. The company states that these transactions together reduced outstanding or potentially issuable shares by 5.8 million year to date.
  • No dividend information is provided in the filing.

What drove it

  • YARTEMLEA gross revenue rose to $41.8 million from $32.2 million, and net revenue rose 26% to $35.9 million from $28.5 million, per the company.
  • The company states that the higher gross-to-net adjustment was driven by higher purchases by 340B-covered entities, consistent with its goal of increasing outpatient utilization and expanding its customer base.
  • The company states that the GAAP net loss of $(57,356) thousand included a non-cash loss of $62.0 million primarily related to mark-to-market adjustments of a derivative associated with the 2029 Notes.
  • Income from operations was $4,501 thousand in the third quarter compared with $0.1 million in the second quarter, per the release.
  • Interest and other income fell to $1.9 million from $4.6 million. The company states the $2.7 million decrease was primarily the result of a reimbursement from Novo for the transfer of zaltenibart inventory recorded in the second quarter.
  • The company states that the NTAP designation for YARTEMLEA became effective on October 1, 2026, providing eligible hospitals up to $287,079 in additional Medicare reimbursement per eligible inpatient case.

Concerns

  • The GAAP net loss of $(57,356) thousand, or $(0.79) per share, reflects a $62.0 million non-cash loss from the change in fair value of financial instruments, compared with a $(8,822) thousand loss in the prior-year quarter.
  • The gross-to-net adjustment rose to 14.0% from 11.5% in the second quarter, as the company explains through higher 340B purchases.
  • In October 2026 the CHMP issued a negative opinion on the MAA for narsoplimab in TA-TMA following re-examination of its June 2026 negative opinion.
  • Total shareholders' deficit was $(89,973) thousand at September 30, 2026.
  • Interest and other income declined to $1,867 thousand from $4.6 million in the prior quarter. The company attributes the decline primarily to a Novo reimbursement recorded in the second quarter.
  • Receivables increased to $23,096 thousand from $10,917 thousand at December 31, 2025.

What to watch

  • Whether YARTEMLEA revenue continues to grow in the fourth quarter, which the CEO states has continued.
  • Trend in the gross-to-net adjustment as 340B participation expands, following the 14.0% level in Q3 2026.
  • Effect of the NTAP designation effective October 1, 2026, and of favorable Medicare outpatient reimbursement for 340B-acquired YARTEMLEA beginning January 1, 2027.
  • Mark-to-market swings in the derivative associated with the 2029 Notes, which drove the Q3 non-cash loss.
  • Initiation timing of the two YARTEMLEA studies in ARDS and pediatric TA-TMA prevention, anticipated in late 2026 or early 2027.
  • Start of OMS527 enrollment in Q1 2027, subject to the nonclinical study the company is conducting for FDA.
  • Zaltenibart Phase 3 initiation by Novo, and the expected near-term milestone payments of up to $100 million.
  • Completion of Novo transition services, which the company expects by mid-2027.
  • Planned start of the OncotoX-AML Phase 1b trial in late 2027.

Balance sheet and cash flow

  • Cash and cash equivalents: $5,070 thousand at September 30, 2026 versus $9,660 thousand at December 31, 2025.
  • Short-term investments: $90,180 thousand at September 30, 2026 versus $162,144 thousand at December 31, 2025.
  • Receivables: $23,096 thousand at September 30, 2026 versus $10,917 thousand at December 31, 2025.
  • Total current assets: $150,893 thousand at September 30, 2026 versus $215,667 thousand at December 31, 2025.
  • Total assets: $248,095 thousand at September 30, 2026 versus $325,632 thousand at December 31, 2025.
  • 2026 Notes, net: nil at September 30, 2026 versus $17,063 thousand at December 31, 2025.
  • 2029 Notes, non-current, net: $31,891 thousand at September 30, 2026 versus $51,364 thousand at December 31, 2025.
  • 2029 Notes embedded derivative, non-current: $101,136 thousand at September 30, 2026 versus $157,171 thousand at December 31, 2025.
  • OMIDRIA royalty obligation, non-current: $130,624 thousand at September 30, 2026 versus $147,319 thousand at December 31, 2025.
  • Total shareholders' deficit: $(89,973) thousand at September 30, 2026 versus $(121,231) thousand at December 31, 2025.
  • Operating cash flow of $13.3 million was generated in the third quarter of 2026. The company states it generated positive operating cash flow in consecutive quarters.

Analysis

Omeros reported third quarter 2026 results in which YARTEMLEA, its approved product for stem cell transplant-associated thrombotic microangiopathy, generated gross revenue of $41.8 million and net product sales of $35,934 thousand. The company states that gross revenue rose 29.6% from $32.2 million in the second quarter and that net revenue rose 26% from $28.5 million. Product sales in the prior-year quarter are shown as a dash in the statements, so no year-over-year growth rate is printed for the product line. Total costs and expenses were $31,433 thousand, compared with $26,392 thousand a year earlier. Income from operations was $4,501 thousand, against $0.1 million in the second quarter, and nine-month operating loss narrowed to $(12,846) thousand from $(93,715) thousand.

The gross-to-net adjustment widened to 14.0% from 11.5%. The company attributes the increase to higher purchases by 340B-covered entities, which it links to its goals of increasing outpatient utilization and expanding its customer base. Cost of product sales was $826 thousand in the quarter. Gross margin is not printed in the filing, so the reader cannot see product-level profitability directly from the document.

Below the operating line, the quarter was dominated by a non-cash item. The net loss from continuing operations was $(63,825) thousand, mainly because of a $(62,020) thousand change in the fair value of financial instruments. GAAP net loss was $(57,356) thousand, or $(0.79) per share, after $6,469 thousand of income from discontinued operations. The company's non-GAAP adjusted net income excludes the remeasurement and was $4,664 thousand, or $0.06 per share, against $1,785 thousand in the second quarter. Interest and other income fell to $1,867 thousand from $4.6 million, which the company attributes primarily to a Novo reimbursement recorded in the second quarter.

On the balance sheet, cash and short-term investments were $95.3 million at September 30, 2026, and operating cash flow was $13.3 million for the quarter. Total shareholders' deficit narrowed to $(89,973) thousand from $(121,231) thousand at December 31, 2025, and the 2029 Notes embedded derivative fell to $101,136 thousand from $157,171 thousand. The company repurchased $30.5 million principal of 2029 Notes for $60.2 million plus accrued interest, leaving about $40.3 million outstanding. These repurchases reduced potentially issuable shares by about 4.9 million, and the company reports $8.6 million of eliminated scheduled interest payments.

The filing gives no quantitative guidance for the coming period. The forward-looking points are qualitative: NTAP became effective October 1, 2026, Medicare outpatient reimbursement for 340B-acquired YARTEMLEA is expected to be favorable from January 1, 2027, and several pipeline milestones are targeted for late 2026 through 2027. Against these, the company disclosed a negative CHMP opinion for narsoplimab in TA-TMA in October 2026, which is a material regulatory setback for the European opportunity.

Management, verbatim

YARTEMLEA sales continued to grow during the third quarter, delivering consecutive quarters of positive operating cash flow.

Gregory A. Demopulos, M.D., Chairman and Chief Executive Officer

As expected, 340B participation increased, reflecting substantial expansion of our customer base and increased outpatient use of YARTEMLEA.

Gregory A. Demopulos, M.D., Chairman and Chief Executive Officer

Not in the filing

stated, not guessed
  • Gross margin or gross profit on product sales: not printed in the filing.
  • Financial guidance for revenue, gross margin, operating expenses or tax rate: none provided in the filing.
  • Prior-year gross YARTEMLEA revenue and prior-year gross-to-net adjustment: not printed.
  • Prior-quarter (Q2 2026) separate R&D and SG&A figures: only their combined total is printed in MD&A.
  • Prior-quarter cost of product sales, total costs and expenses, and SG&A: not printed.
  • Year-over-year and quarter-over-quarter percentage changes for operating income, interest, net loss and per-share lines: not printed.
  • Prior-quarter operating cash flow: not printed, so the statement of consecutive positive quarters is company commentary only.
  • Operating cash flow basis (GAAP or non-GAAP): not labelled in the filing.
  • Dividend information: not in the filing.
  • Consensus estimates, analyst expectations and share-price reaction: not in the filing and not provided.
  • Discrepancy: the highlights section gives the Q2 2026 non-cash gain as $11.5 million, while the Financial Results section gives $11.4 million; the reconciliation shows 11,447 thousand. The $11.4 million figure is used in the table row, and the discrepancy is noted here.
  • Interest expense (net) and remeasurement lines in the schedule are presented with mixed signs; the 2025 comparatives are copied as printed.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second quarter of 2026

AlphAI · Earnings readOMER · Second quarter of 2026 · ended June 30, 2026

Omeros reported $28.5 million of second-quarter net revenue from the first full quarter of YARTEMLEA’s commercial launch, generated GAAP net income of $13.2 million, and completed debt and share repurchases in July.

✓Solid quarter

YARTEMLEA revenue increased 190% sequentially, the company generated $4.1 million of operating cash flow and $1.8 million of non-GAAP adjusted net income, while reducing 2029 Notes principal and potential conversion dilution. GAAP net income declined sequentially because non-cash gains were substantially lower, and the European MAA received a negative CHMP opinion.

Revenue
$28.5M
YARTEMLEA
$32.2M
190% q/q
EPS · non-GAAP
$0.02

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net revenueGAAP$28.5M––
YARTEMLEA gross revenuesother$32.2M190%–
Gross-to-net adjustmentsotherapproximately 11.5%––
Net incomeGAAP$13.2M––
Net income per shareGAAP$0.18 per share––
Adjusted net incomenon-GAAP$1.8M––
Adjusted net income per sharenon-GAAP$0.02 per share––
Non-cash gainsGAAP$11.5M––
Research and development and selling, general and administrative expensesGAAPapproximately $27.7 million––
Operating incomeGAAP$100K––
Interest and other incomeGAAP$4.6M$3.1 million increase–
Net cash provided by operationsGAAP$4.1M––

Segments

SegmentRevenueq/qy/y
YARTEMLEAStrong momentum and growing market acceptance in the first full quarter of YARTEMLEA’s commercial launch.$32.2M190%–

Capital returns

  • During the three months ended June 30, 2026, Omeros repurchased and retired approximately 0.5 million shares of common stock at an average cost of $11.70 per share for an aggregate purchase price of $5.7 million.
  • During the six months ended June 30, 2026, Omeros repurchased and retired approximately 0.8 million shares of common stock at an average cost of $11.70 per share for an aggregate purchase price of $9.9 million.
  • In July 2026, Omeros completed the repurchase of $30.5 million aggregate principal amount of 2029 Notes for a total purchase price of $60.2 million.
  • The 2029 Notes repurchases reduced the aggregate number of shares issuable upon conversion from approximately 11.4 million to 6.5 million and eliminated $8.6 million in future interest payments.

What drove it

  • YARTEMLEA gross revenues increased by $21.1 million from the first quarter of 2026.
  • Interest and other income increased primarily because of a reimbursement from Novo Nordisk for the transfer of zaltenibart inventory.
  • The permanent Healthcare Common Procedure Coding System J-code specific for YARTEMLEA became effective on July 1, 2026.
  • CMS granted NTAP status to YARTEMLEA, effective October 1, 2026, to provide eligible hospitals with additional Medicare reimbursement for inpatient cases involving YARTEMLEA.

Concerns

  • CHMP adopted a negative opinion on Omeros’ MAA for narsoplimab in TA-TMA in June. Omeros has requested re-examination.
  • GAAP net income declined from $56.1 million in the first quarter of 2026 to $13.2 million in the second quarter, as non-cash gains declined from $73.1 million to $11.5 million.
  • Gross-to-net adjustments were approximately 11.5% in the second quarter compared with approximately 11.0% in the first quarter.
  • Research and development and selling, general and administrative expenses totaled approximately $27.7 million compared with $26.7 million in the first quarter.

What to watch

  • The re-examination of the negative CHMP opinion for the narsoplimab MAA in TA-TMA, including review by an Ad Hoc Expert Group.
  • The effect of NTAP status for YARTEMLEA beginning October 1, 2026.
  • Expected enrollment by year-end 2026 in two investigator-sponsored and Omeros-supported YARTEMLEA studies.
  • Expected start of enrollment in the OMS527 inpatient clinical trial by year-end 2026.
  • Phase 3 trial initiation for zaltenibart with Novo Nordisk.
  • The targeted late 2027 start of the first-in-human Phase 1b clinical trial for OMS805.

Balance sheet and cash flow

  • At June 30, 2026, Omeros had $132.0 million of cash and short-term investments.
  • For the three months ended June 30, 2026, company-wide net cash provided by operations was $4.1 million.
  • Approximately $40.3 million aggregate principal amount of 2029 Notes remains outstanding.
  • The July 2026 2029 Notes transactions had a total purchase price of $60.2 million, plus accrued and unpaid interest of $0.2 million.
  • Omeros achieved the reduction in shares issuable on conversion at a weighted average cost of $12.21 per share.

Analysis

The second quarter showed a substantial step-up in YARTEMLEA commercialization. YARTEMLEA gross revenues were $32.2 million, up 190% from $11.1 million in the first quarter, while net revenue was $28.5 million compared with $9.9 million. The company described the period as the first full quarter of YARTEMLEA’s commercial launch and cited growing market acceptance. Gross-to-net adjustments were approximately 11.5%, compared with approximately 11.0% in the first quarter.

Operating results improved alongside revenue growth. Omeros reported operating income of $0.1 million, compared with an operating loss of $17.4 million in the first quarter, and generated $4.1 million of company-wide net cash provided by operations. Research and development and selling, general and administrative expenses totaled approximately $27.7 million, compared with $26.7 million in the first quarter. Interest and other income increased to $4.6 million from $1.5 million, primarily due to a reimbursement from Novo Nordisk for the transfer of zaltenibart inventory.

GAAP net income was $13.2 million, or $0.18 per share, versus $56.1 million, or $0.78 per share, in the first quarter. The sequential decline reflects the reduction in non-cash gains to $11.5 million from $73.1 million, primarily related to the mark-to-market adjustment of the embedded derivative associated with the 2029 Notes. Excluding those non-cash gains, non-GAAP adjusted net income was $1.8 million, or $0.02 per share, compared with a non-GAAP adjusted net loss of $17.1 million, or $0.24 per share.

Capital allocation focused on both equity and debt reduction. Omeros had $132.0 million of cash and short-term investments at June 30, 2026, repurchased and retired approximately 0.5 million shares during the quarter for $5.7 million, and completed 2029 Notes repurchases in July. The note transactions reduced outstanding principal to approximately $40.3 million, reduced shares issuable upon conversion from approximately 11.4 million to 6.5 million, and eliminated $8.6 million in future interest payments.

The company provided no financial guidance in the filing. Operational attention centers on the effect of the YARTEMLEA J-code and NTAP designation, the requested re-examination of the negative CHMP opinion on the narsoplimab MAA, and progression of pipeline programs. Omeros expects enrollment to begin by year-end 2026 in two YARTEMLEA-supported studies and expects to be able to start enrollment in the OMS527 inpatient clinical trial by year-end 2026. The filing also states that work with Novo Nordisk on zaltenibart remained on track toward Phase 3 trial initiation.

Management, verbatim

We are very pleased with the strong momentum and growing market acceptance in the first full quarter of YARTEMLEA’s commercial launch.

Gregory A. Demopulos, M.D., Omeros’ Chairman and Chief Executive Officer

Substantial second-quarter YARTEMLEA revenues have enabled us to continue strengthening our capital structure.

Gregory A. Demopulos, M.D., Omeros’ Chairman and Chief Executive Officer

Not in the filing

stated, not guessed
  • Prior-year total revenue, net revenue, YARTEMLEA gross revenue, gross-to-net adjustments, net income, EPS, operating income, operating expenses, interest and other income, and operating cash flow were not reported.
  • GAAP gross margin and non-GAAP gross margin were not reported.
  • Individual research and development expense and selling, general and administrative expense were not reported.
  • Free cash flow was not reported.
  • Diluted share count was not reported.
  • Tax rate was not reported.
  • Dividend information was not reported.
  • Financial guidance for revenue, gross margin, operating expenses, tax rate, or other financial metrics was not reported.
  • A previous-quarter outlook section was not provided.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about OMER earnings dates

When is Omeros's next earnings date?
AlphAI has no date for OMER yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.